Utility of B-Type Natriuretic Peptide as a Screen for Left Ventricular Dysfunction in Patients With Diabetes

Response to Epshteyn et al.

  1. Danny Liew, FRACP1,
  2. Hans Schneider, FRACP2,
  3. Joe D’Agostino, BSC2,
  4. Jonathan Shaw, MD3 and
  5. Henry Krum, PHD1
  1. 1NHMRC Centre of Clinical Research Excellence in Therapeutics, Department of Epidemiology and Preventive Medicine, Monash University Medical School, Alfred Hospital, Melbourne, Victoria, Australia
  2. 2Alfred Pathology Service, Alfred Hospital, Melbourne, Victoria, Australia
  3. 3International Diabetes Institute, Caulfield, Victoria, Australia
  1. Address correspondence to Dr. Danny Liew, Department of Epidemiology and Preventive Medicine, Monash University Medical School, Alfred Hospital, Melbourne, Victoria 3004, Australia. E-mail: danny.liew{at}med.monash.edu.au

In their study recently published in Diabetes Care, Epshteyn et al. (1) found that plasma B-type natriuretic peptide (BNP) was able to discriminate between diabetic patients with and without left ventricular (LV) dysfunction, even among the subset without any clinical suspicion of heart failure. It is this last observation that supports the use of BNP as a screen for LV dysfunction among people with diabetes. Detection of LV dysfunction, an early feature of diabetic heart disease, presents an important opportunity for prevention of …

| Table of Contents